 | |
| Clinical data | |
|---|---|
| Pronunciation | /duːˌkrævəˈsɪtɪnɪb/ doo-KRA-və-SI-ti-nib |
| Trade names | Sotyktu |
| Other names | BMS-986165 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category | |
| Routes of administration | By mouth |
| Drug class | Tyrosine kinase 2 (TYK2)inhibitor |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 99% |
| Protein binding | 82–90% |
| Metabolism | Liver (primarilyCYP1A2) |
| Metabolites | BMT-153261 (active) |
| Eliminationhalf-life | 10 hours |
| Excretion | Feces, urine |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| ECHA InfoCard | 100.329.069 |
| Chemical and physical data | |
| Formula | C20H19D3N8O3 |
| Molar mass | 425.466 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Deucravacitinib, sold under the brand nameSotyktu, is amedication used for the treatment of moderate-to-severeplaque psoriasis.[7] It is atyrosine kinase 2 (TYK2)inhibitor and it is takenby mouth.[7] It was developed byBristol Myers Squibb.[10]
Deucravacitinib was approved for medical use in the United States in September 2022,[7][11][12] and in Australia in December 2022.[1] The USFood and Drug Administration (FDA) considers it to be afirst-in-class medication.[13][14]
Deucravacitinib isindicated for the treatment of adults with moderate-to-severe plaque psoriasis.[7]
It acts as a highly selectiveallosteric inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2).[15]
The chemical structure of deucravacitinib contains a methyl amide in which all three hydrogen atoms arereplaced bydeuterium.[16]
In January 2023, theCommittee for Medicinal Products for Human Use (CHMP) of theEuropean Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Sotyktu, intended for the treatment of moderate to severe psoriasis.[8][17] The applicant for this medicinal product is Bristol-Myers Squibb Pharma EEIG.[8][17] Deucravacitinib was approved for medical use in the European Union in March 2023.[8]
This article incorporates text from this source, which is in thepublic domain. This article incorporates text from this source, which is in thepublic domain.